ALXN News and Press, Alexion Pharmaceuticals Inc.

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-10-27 11:56:53 ET Summary Xencor is expected to release data from a phase 2 study in early 2024 targeting patients with mCRPC and gynecological cancers, which could generate shareholder value. The global metastatic castration-resistant prostate cancer treatment market is expe...

2023-05-19 11:27:29 ET BofA Securities has initiated Xencor ( NASDAQ: XNCR ) with a buy highlighting its pipeline of protein therapeutics for cancer and inflammatory diseases. The firm has a $42 price target (~61% upside based on Thursday's close) in Friday morning trading. ...

2023-03-16 18:45:17 ET Summary BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch. The good growth in forms approved so far makes me very optimistic about th...

Summary Today we take our first look at Apellis Pharmaceuticals, a midcap concern with an advancing pipeline. Its flagship product was rolled out last year, is pursuing other indications, and could eventually achieve blockbuster status. However, some insiders are selling and q...

Baker Brothers’ 13F portfolio value decreased from $23.07B to $22.77B this quarter. The InVitae stake was reduced this quarter while increasing Apellis Pharma and Heron Therapeutics. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almo...

Jeremy Grantham’s 13F portfolio value increased from $18.31B to $20.05B this quarter. GMO Capital increased Kansas City Southern and Otis Worldwide while reducing Lyft, Baidu, and Charles Schwab. The largest three individual stock positions are Microsoft Corporation, Alphab...

Soros' 13F portfolio value increased from $5.33B to $5.93B this quarter. The number of positions increased from 229 to 257. Soros increased Amazon.com while reducing QuantumScape and dropping Baidu, Tencent Music Group, ViacomCBS, and Vipshop Holdings. Liberty Broadband at ~12% of...

Zoom uses its expensive stock to enter adjacent market with the acquisition of Five9 for $14.7 billion. Monmouth Real Estate Investment Corporation's board supports the pending merger of MNR with Equity Commonwealth after receiving a competing offer from Starwood. Salesforce compl...